Evidence map›Paper›PMID 20515459›Full record

ArticleBMC musculoskeletal disorders2010

Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption--implications for osteoclast quality.

Anita V Neutzsky-Wulff, Mette G Sørensen, Dino Kocijancic, Diana J Leeming, Morten H Dziegiel, Morten A Karsdal, Kim Henriksen

Open access · goldAbstract readComparative Study
In one paragraph

Article in BMC musculoskeletal disorders, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. GPDPLQScientific reports · 2019
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Anita V Neutzsky-WulffNordic Bioscience A/S, Herlev DK 2730, Denmark.
Mette G Sørensen
Dino Kocijancic
Diana J Leeming
Morten H Dziegiel
Morten A Karsdal
Kim Henriksen
Nordic Bioscience (Denmark) · DKCopenhagen University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNormal osteoclasts resorb bone by secretion of acid and proteases. Recent studies of patients with loss of function mutations affecting either of these processes have indicated a divergence in osteoclastic phenotypes. These difference in osteoclast phenotypes may directly or indirectly have secondary effects on bone remodeling, a process which is of importance for the pathogenesis of both osteoporosis and osteoarthritis. We treated human osteoclasts with different inhibitors and characterized their resulting function.

methodsHuman CD14 + monocytes were differentiated into mature osteoclasts using RANKL and M-CSF. The osteoclasts were cultured on bone in the presence or absence of various inhibitors: Inhibitors of acidification (bafilomycin A1, diphyllin, ethoxyzolamide), inhibitors of proteolysis (E64, GM6001), or a bisphosphonate (ibandronate). Osteoclast numbers and bone resorption were monitored by measurements of TRACP activity, the release of calcium, CTX-I and ICTP, as well as by counting resorption pits.

resultsAll inhibitors of acidification were equally potent with respect to inhibition of both organic and inorganic resorption. In contrast, inhibition of proteolysis by E64 potently reduced organic resorption, but only modestly suppressed inorganic resorption. GM6001 alone did not greatly affect bone resorption. However, when GM6001 and E64 were combined, a complete abrogation of organic bone resorption was observed, without a great effect on inorganic resorption. Ibandronate abrogated both organic and inorganic resorption at all concentrations tested [0.3-100 microM], however, this treatment dramatically reduced TRACP activity.

conclusionsWe present evidence highlighting important differences with respect to osteoclast function, when comparing the different types of osteoclast inhibitors. Each class of osteoclast inhibitors will lead to different alterations in osteoclast quality, which secondarily may lead to different bone qualities.

Indexed as

AnimalsBone Density Conservation AgentsBone ResorptionCattleCell Culture TechniquesCell DifferentiationCells, CulturedDiphosphonatesEnzyme InhibitorsHumansIbandronic AcidLeucineMacrolidesMacrophage Colony-Stimulating FactorMonocytesOsteoclastsbafilomycin A1Bone Density Conservation AgentsDiphosphonatesE 64Enzyme InhibitorsIbandronic AcidLeucineMacrolidesMacrophage Colony-Stimulating FactorProtease InhibitorsRANK LigandTNFSF11 protein, human

Identifiers

PMID20515459
PMCPMC2891608
OpenAlexW2109027220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.